California State Teachers Retirement System lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 152,549 shares of the biopharmaceutical company’s stock after buying an additional 8,213 shares during the period. California State Teachers Retirement System’s holdings in Alnylam Pharmaceuticals were worth $14,256,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Parametric Portfolio Associates LLC lifted its stake in Alnylam Pharmaceuticals by 43.4% during the 1st quarter. Parametric Portfolio Associates LLC now owns 139,969 shares of the biopharmaceutical company’s stock valued at $13,080,000 after acquiring an additional 42,369 shares in the last quarter. First Trust Advisors LP lifted its stake in Alnylam Pharmaceuticals by 1.2% during the 1st quarter. First Trust Advisors LP now owns 1,192,495 shares of the biopharmaceutical company’s stock valued at $111,439,000 after acquiring an additional 14,439 shares in the last quarter. Piedmont Investment Advisors Inc. lifted its stake in Alnylam Pharmaceuticals by 6.5% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 6,118 shares of the biopharmaceutical company’s stock valued at $572,000 after acquiring an additional 371 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in Alnylam Pharmaceuticals by 34.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 52,412 shares of the biopharmaceutical company’s stock valued at $4,886,000 after acquiring an additional 13,287 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Alnylam Pharmaceuticals by 66.2% during the 1st quarter. US Bancorp DE now owns 369 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 147 shares in the last quarter. 89.78% of the stock is owned by institutional investors.

In related news, CEO John Maraganore sold 49,457 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $70.00, for a total value of $3,461,990.00. Following the completion of the sale, the chief executive officer now owns 239,450 shares of the company’s stock, valued at approximately $16,761,500. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $88.23, for a total value of $1,323,450.00. Following the completion of the sale, the director now directly owns 250,633 shares of the company’s stock, valued at approximately $22,113,349.59. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.

ALNY has been the topic of several recent analyst reports. Morgan Stanley upgraded Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price objective on the stock in a research note on Tuesday, March 5th. ValuEngine cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. BMO Capital Markets raised their price objective on Alnylam Pharmaceuticals from $126.00 to $128.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Evercore ISI started coverage on Alnylam Pharmaceuticals in a research note on Thursday, April 11th. They set an “outperform” rating and a $120.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $135.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, February 8th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus price target of $127.44.

NASDAQ ALNY opened at $66.87 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $60.27 and a one year high of $124.21. The company has a quick ratio of 9.12, a current ratio of 9.33 and a debt-to-equity ratio of 0.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.20) by $0.47. The company had revenue of $33.29 million for the quarter, compared to analysts’ expectations of $21.60 million. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The business’s revenue for the quarter was up 52.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.22) EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -8.48 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Stake Increased by California State Teachers Retirement System” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2019/06/04/alnylam-pharmaceuticals-inc-alny-stake-increased-by-california-state-teachers-retirement-system.html.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Recommended Story: Hedge Funds – How They Work For Investors

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.